Last reviewed · How we verify
BMI2006
BMI2006 is a small molecule drug that targets the SGLT2 receptor.
BMI2006 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | BMI2006 |
|---|---|
| Also known as | Clostridium botulinum Type A |
| Sponsor | BMI Korea |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, BMI2006 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |